Hepatoprotective effect of a novel lactic acid-fermented garlic extract functional food product against acute liver injury

Lactic acid-fermented garlic extract (LAFGE) has been shown to have hepatoprotective role in liver diseases. This study was conducted to evaluate the efficacy of a new LAFGE-based hepatoprotective functional food product (named D-18-007) formulated with other additive components, including l-arginine, l-ornithine, and the leaf extract of licorice and artichoke. In a rat model of d-galactosamine(GalN)/LPS-induced liver injury, the survival was significantly higher in animals treated with D-18-007 than in animals treated with LAFGE. The hepatic injury was alleviated by either LAFGE or D-18-007, but the overall effect was more significant in D-18-007, as shown by the necrosis, histology, and serum analyses. Also, the decrease in GalN/LPS-induced lipid peroxidation in the liver tissue was more significant in D-18-007 than LAFGE. The decrease in IL-6 protein in the liver was similar between LAFGE and D-18-007. Moreover, we compared the amount of the bile in normal animals and found that D-18-007 has better choleretic activity than LAFGE. Using this acute liver injury model, our results suggest that D-18-007 has an enhanced hepatoprotective effect in acute liver injury compared with LAFGE alone.

Hepatoprotective effects of lactic acid-fermented garlic extract against acetaminophen-induced acute liver injury in rats

The aim of the present study was to investigate the protective effect of fermented garlic extract by lactic acid bacteria (LAFGE) against acetaminophen (AAP)-induced acute liver injury in rats. Here we demonstrated that rats treated with LAFGE exhibit resistance to AAP-induced liver injury accompanied by lowered plasma alanine amino transferase levels and decreased proinflammatory responses. This function of LAFGE is linked to its capacity of suppressing AAP-induced apoptosis in the liver, partly via the inhibition of MAPK phosphorylation as well as down-regulation of p53. Our findings reveal that LAFGE modulates the signaling pathways involved in hepatic apoptosis through cellular redox control, as indicated by the inhibition of lipid peroxidation, glutathione and ATP depletion, and the elevation of antioxidant enzyme activities. Taken together, these findings indicate that LAFGE ameliorates AAP-induced liver injury by preventing oxidative stress-mediated apoptosis, thereby establishing LAFGE as a potential supplement in the treatment of AAP-induced liver injury.